Loss of secreted phospholipase A2 receptor (PLA2R1) has recently been found to render human primary cells more resistant to senescence whereas increased PLA2R1 expression is able to induce cell cycle arrest, cancer cell death or blockage of cancer cell transformation in vitro, suggesting that PLA2R1 displays tumor suppressive activities. Here we report that PLA2R1 expression strongly decreases in samples of human renal cell carcinoma (RCC). Knockdown of PLA2R1 increases renal cancer cell tumorigenicity supporting a role of PLA2R1 loss to promote in vivo RCC growth. Most RCC result from Von Hippel-Lindau (VHL) tumor suppressor loss-of-function and subsequent gain-of-function of the oncogenic HIF-2alpha/c-MYC pathway. Here, by genetically man...
SummaryThe PP2A serine/threonine protein phosphatase serves as a critical cellular regulator of cell...
Regulation of immunity is a unique oncogenic mechanism that differs in different cancers. VHL defici...
Summaryvon Hippel-Lindau (VHL) tumor suppressor loss results in hypoxia-inducible factor alpha (HIF-...
Loss of secreted phospholipase A2 receptor (PLA2R1) has recently been found to render human primary ...
International audienceLittle is known about the physiological role of the phospholipase A2 receptor ...
International audienceLittle is known about the biological functions of the phospholipase A2 recepto...
Protein phosphatase 2A (PP2A) complexes counteract many oncogenic kinase pathways. In cancer cells, ...
International audienceAlthough aging is a major risk factor for most types of cancers, it is barely ...
International audienceSenescence is a stable proliferative arrest induced by various stresses such a...
Protein Phosphatase 2A (PP2A) enzymes counteract diverse kinase-driven oncogenic pathways and their ...
Protein Phosphatase 2A (PP2A) enzymes counteract diverse kinase-driven oncogenic pathways and their ...
Item does not contain fulltextBiallelic mutations of the von Hippel-Lindau (VHL) gene are the most c...
Clear cell renal cell carcinoma (ccRCC) is the most frequent type of kidney cancer, with 50% 5-year ...
Protein Phosphatase 2A (PP2A) complexes counteract diverse kinase-driven oncogenic pathways. Accumul...
AbstractEpigenetic changes provide a frequent mechanism for transcriptional silencing of genes in ca...
SummaryThe PP2A serine/threonine protein phosphatase serves as a critical cellular regulator of cell...
Regulation of immunity is a unique oncogenic mechanism that differs in different cancers. VHL defici...
Summaryvon Hippel-Lindau (VHL) tumor suppressor loss results in hypoxia-inducible factor alpha (HIF-...
Loss of secreted phospholipase A2 receptor (PLA2R1) has recently been found to render human primary ...
International audienceLittle is known about the physiological role of the phospholipase A2 receptor ...
International audienceLittle is known about the biological functions of the phospholipase A2 recepto...
Protein phosphatase 2A (PP2A) complexes counteract many oncogenic kinase pathways. In cancer cells, ...
International audienceAlthough aging is a major risk factor for most types of cancers, it is barely ...
International audienceSenescence is a stable proliferative arrest induced by various stresses such a...
Protein Phosphatase 2A (PP2A) enzymes counteract diverse kinase-driven oncogenic pathways and their ...
Protein Phosphatase 2A (PP2A) enzymes counteract diverse kinase-driven oncogenic pathways and their ...
Item does not contain fulltextBiallelic mutations of the von Hippel-Lindau (VHL) gene are the most c...
Clear cell renal cell carcinoma (ccRCC) is the most frequent type of kidney cancer, with 50% 5-year ...
Protein Phosphatase 2A (PP2A) complexes counteract diverse kinase-driven oncogenic pathways. Accumul...
AbstractEpigenetic changes provide a frequent mechanism for transcriptional silencing of genes in ca...
SummaryThe PP2A serine/threonine protein phosphatase serves as a critical cellular regulator of cell...
Regulation of immunity is a unique oncogenic mechanism that differs in different cancers. VHL defici...
Summaryvon Hippel-Lindau (VHL) tumor suppressor loss results in hypoxia-inducible factor alpha (HIF-...